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abstract
Since its inception in 1969, the EORTC Melanoma Group has employed a
multidisciplinary approach in the ﬁght against melanoma and has registered
signiﬁcant achievements in many areas of melanoma treatment and research. The
group showed that sentinel node (SN) tumor burden according to the Rotterdam
Criteria and the microanatomic location were the most important prognostic factors
for melanoma-speciﬁc survival and non-SN positivity in the completion lymph node
dissection specimen. They demonstrated that extended schedule escalated dose
temozolomide is feasible and has an acceptable safety proﬁle. They also showed that
the interferon-a targeted therapy should occur in a targeted patient population, and
should probably not be offered to 70% of the patients that are currently being given
this treatment. Through EORTC trial 18991, Sylatron™, pegylated interferon a-2b, for
the treatment of melanoma patients with microscopic or gross nodal involvement
within 84 days of deﬁnitive surgical resection including complete lymphadenectomy,
was approved by the US FDA. The present article describes the achievements and
future strategies of the Melanoma Group.
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1. Introduction
The worldwide incidence of malignant melanoma has
been increasing over the past 30 years with an annual
increase above 2%. 1−3 The disease stage of melanoma
at diagnosis is the major determinant of prognosis and
survival, and though early-stage disease is often cured by
surgical excision of the primary tumor, melanoma with
distant spread is often fatal. 4
The European Organisation for Research andTreatment
of Cancer (EORTC) has been at the forefront of oncology
practice-changing trials throughout the world. In 1969,
the EORTC Melanoma Group (EORTC MG) was one of
the ﬁrst EORTC groups. Founded by a small group
of like-minded colleagues from all over Europe, the
EORTC MG has been and still remains a unique group
within the EORTC as manifested by its multidisciplinary
approach in harnessing all disciplines of the medical
community in the ﬁght against melanoma. Over the
past 40 years successive Chairs of the EORTC MG
have enthusiastically fostered the collaboration of
immunologists, pathologists, and clinicians, and the
young investigators platform of the EORTC MG offers
a unique forum for development of budding melanoma
researchers.
The EORTC MG has always pursued an unwavering
interest in tumor biology with a special focus on the
immunological aspects of melanoma. The group has
successfully performed many clinical, epidemiological,
histopathological, and surgical studies that have de-
ﬁned standards and guidelines in the management
of melanoma. There has been a great emphasis on
translational research with respect to the prognostic
factors and various metastatic and immunological
aspects of melanoma. This led to the development
of quality assurance programs for immunological and
molecular biological assays in laboratory networks.
The EORTC MG currently has subcommittees con-
cerned with the management of cutaneous and oc-
ular melanoma which focus on the development of
new treatment strategies and conducting epidemiolog-
ical, genetic, and pathological research on melanoma.
These comprise adjuvant therapy, systemic therapy
for advanced disease, epidemiology, genetics, ocular
melanoma, pathology, surgery, translational research in
melanoma (an ‘umbrella’ subcommittee), and Young
Investigator subcommittees.
2. Major advances
2.1. Status of the sentinel node in melanoma
The sentinel node (SN) procedure was introduced in
penile cancer by Cabanas in the late 1970’s. 5 With the
introduction of lymphatic mapping, it was adapted by
Donald Morton and colleagues in the 1990’s to the
situation in melanoma. 6,7 Since then, the SN procedure
has become standard of care for the staging of melanoma
patients in many countries. However,many controversies
still remain, which have led to an enormous amount of
research on the subject of the SN in melanoma and in
which the EORTC MG has played a prominent role.
One of the groundbreaking achievements was the
analysis and implementation of an optimal pathology
protocol for the work-up of SNs in melanoma. A study
by Cook et al. on behalf of the EORTC MG analyzed a
number of different protocols with respect to the type
and extent of the pathology work-up of SNs. 8 This study
demonstrated a massive 42% increase in SN positivity
rate and thus also led to a signiﬁcant reduction in
false negative rates. 4 Since 2003, this protocol has been
implemented by the entire EORTC MG network and in all
EORTC MG protocols.
At the same time the analysis of SN metastases with
regard to their extent and intranodal site has become
equally important. A paper by the EORTC MG analyzed
practical issues with respect to difﬁculties in the analyses
of SN tumor burden and the SN microanatomic location
of metastases. 5 These analyses led to recommendations
and guidelines for the analysis of these factors and have
been implemented by the EORTC MG network. 9
A multicenter EORTC MG study by van der Ploeg
et al. 10 has reviewed the largest dataset of SNs
worldwide. In 1080 SN-positive melanoma patients
(1993–2008), SN tumor burden deﬁned by the Rotterdam
Criteria according to van Akkooi et al. 11 and the
microanatomic location according to Dewar et al. 12 were
the most important prognostic factors for melanoma-
speciﬁc survival and non-SN positivity in the completion
lymph node dissection (CLND) specimen. Patients with
minimal SN tumor burden might therefore safely be
spared a routine CLND.
The EORTC MG has launched a prospective registration
study, the MINITUB. Patients with minimal SN tumor
burden will be managed without routine CLND. Simul-
taneously, SN tumor burden has become an important
issue in the adjuvant interferon (IFN) studies. SN tumor
burden has become an important stratiﬁcation tool for
all new adjuvant studies in melanoma and we look to
integrating this in future studies of EORTC MG.
2.2. IFN in melanoma
The EORTC MG has been at the forefront of evaluating
interferon in melanoma patients. Two landmark studies
were published, and they are described brieﬂy below.
2.2.1. EORTC trial 18952 − Post-surgery adjuvant therapy
with intermediate doses of interferon alfa-2b versus
observation in patients with stage IIb/III melanoma 13
Background: Treatment with high-dose and low-dose in-
terferon alfa had been evaluated, with the former having
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substantial toxicity and a consistent effect on relapse-
free survival (RFS) but not on overall survival (OS), and
the latter having no consistent effect on either. Hence,
the objective of this trial was to assess the efﬁcacy and
toxicity of two regimens of interferon of intermediate
dose versus observation.
Methods: EORTC trial 18952 was a randomized con-
trolled trial involving 1388 patients with thick primary
tumors (thickness4mm) resected (stage IIb) or regional
lymph node metastases dissected (stage III). Patients
were randomly allocated to a 13-month (n=553) or
25-month (n=556) treatment arm with subcutaneous
interferon alfa-2b, or observation (n=279). Treatment
consisted of 4 weeks of 10million units (MU) of interferon
alfa (5 days per week) followed by either 10MU 3 times a
week for 1 year or 5MU 3 times a week for 2 years, for a
total dose of 1760MU. The primary endpoint was distant
metastasis-free interval (DMFI) and OS was secondary
endpoint. Data were analyzed following the intent to
treat principle.
Findings: The 25-month interferon group presented an
increase of 7.2% in the DMFI rate at 4.5 years (hazard ratio
[HR] = 0.83, 97.5% conﬁdence interval [CI] 0.66−1.03) as
well as a 5.4% improvement in OS. In comparison, the 13-
month interferon treatment arm showed a 3.2% increase
in rate of DMFI at 4.5 years (HR=0.93, 97.5%CI 0.75–1.16)
while no signiﬁcant impact on the OS was found. Toxicity
was acceptable with 18% (195 of 1076) of patients going
off study because of toxicity or as a result of refusal of
treatment because of side-effects.
Interpretation: The interferon alfa regimens tested
in the study did not improve outcome for patients
with stage IIb/III melanomas, and therefore cannot
be recommended. Notably, the duration of treatment
seemed more important than dose, and should be
assessed in future study proposals.
2.2.2. EORTC 18991 − Adjuvant therapy with pegylated
interferon alfa-2b versus observation alone in resected
stage III melanoma 14
Background: Any beneﬁt of adjuvant interferon alfa-2b
for melanoma could depend on dose and duration of
treatment. Our aim was to determine whether pegylated
interferon alfa-2b can facilitate prolonged exposure
while maintaining tolerability.
Methods: A total number of 1256 patients with resected
stage III melanoma were randomly assigned to obser-
vation (n=629) or pegylated interferon alfa-2b (n=627)
6mg/kg per week for 8 weeks (induction) then 3 mg/kg per
week (maintenance) for an intended duration of 5 years.
Randomization was stratiﬁed for microscopic (N1) versus
macroscopic (N2) nodal involvement, number of positive
nodes, ulceration and tumor thickness, sex, and center.
The primary endpoint was recurrence-free survival (RFS).
Analyses were done by intention to treat.
Findings: The median length of treatment with pegy-
lated interferon alfa-2b was 12 months (IQR 3.8–33.4).
At 3.8 years (3.2−4.2) median follow-up, 328 recurrence
events had occurred in the interferon group compared
with 368 in the observation group (HR=0.82, 95%CI 0.71–
0.96; p= 0.01); the 4-year rate of RFS was 45.6% (SE 2.2%) in
the interferon group and 38.9% (2.2%) in the observation
group.There was no difference in OS between the groups.
A total of 608 patients in the interferon group and 613
patients in the observation group were included in safety
analyses. Grade 3/4 adverse events occurred in 246 (40%)/
32 (5%) patients in the interferon group and 60 (10%)/
14 (2%) in the observation group. In the interferon group,
the most common grade 3 or 4 adverse events were
fatigue (97 patients, 16%), hepatotoxicity (66, 11%), and
depression (39, 6%). Treatment with pegylated interferon
alfa-2b was discontinued because of toxicity in 191 (31%)
patients.
Interpretations: The ﬁnal conclusion was that adjuvant
pegylated interferon alfa-2b for stage III melanoma has
a signiﬁcant, sustained effect on RFS. FDA has approved
this drug based on this trial for this indication.
2.2.3. Meta-analysis
Background: As ulcerated (Ulc) melanomas have a
worse prognosis than non-ulcerated (N-Ulc) melanomas,
resulting from a difference in biology, the outcome
after adjuvant IFN therapy in the two above mentioned
phase III trials (EORTC 18952 and 18991) was analyzed. 15
Methods: Using meta-analytical methods, predictive
value for Ulc on the value of IFN on relapse-free survival
(RFS), DMFS, and OS was evaluated among a total of 2644
patients.
Findings: In the Ulc group, representing a total of 849
patients, the treatment effect was much greater than in
the N-Ulc group for RFS (Test For Interaction: p=0.02),
DMFS (p< 0.001), and OS (p< 0.001). The greatest impact
occurred in patients with Ulc and stages IIb/III−N1.
Interpretations: The post hoc analyses of EORTC trials
1892 and 18991 and the consistency in the treatment
impact seen in both indicate strongly that patients with
an Ulc primary are far more sensitive to IFN than
patients with N-Ulc primaries. This hypothesis will now
be tested in the EORTC 18081 trial which compares
PEG-IFNa-2b versus observation in patients with Ulc
primaries >1mm.
2.3. Immunotherapy in melanoma
The EORTCMG has been a leading network for the testing
of new immunotherapies, including vaccines, cytokines
and now new antibodies. Vaccines have been tested in a
variety of cancers with varying success.
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2.3.1. EORTC trial 18961 − Adjuvant phase III study assessing
the efﬁcacy and toxicity of ganglioside GM2-KLH/QS-21
vaccination versus observation in stage II melanoma. 16
Background: Preliminary studies showed that vaccination
with ganglioside GM2-KLH/QS-21 led to responses in
advanced melanoma.
Methods: Patients were randomized between observa-
tion and ganglioside GM2-KLH/QS-21 sc vaccinations
once weekly weeks 1−4, every 3 months from week 12 for
the ﬁrst 2 years and every 6 months during the third year
(total of 14 vaccinations). The primary endpoint was RFS,
and DMFS and OS were secondary endpoints. An intent-
to-treat analysis was performed.
Results: Over a 3-year recruitment period, 1,314
patients were enrolled in the trial. An interim analysis
performed when 267 RFS events were reached showed
that the criteria for stopping for futility were for the
primary endpoint, RFS. In addition, for DMFS and OS,
a trend favoring the observation arm was observed.
Consequently, the EORTC IDMC recommended that
GM2-KLH/QS-21 vaccine be stopped in the patients still
under treatment while patients continued to be followed
for the trial’s endpoints.
Conclusions: Adjuvant GM2-KLH/QS-21 vaccination is
ineffective and could even be detrimental in stage II
melanoma patients.
2.3.2. EORTC trial 18951 − Randomized phase III trial.
Treatment of metastatic melanoma with DTIC, CDDP and
IFN-alpha with or without IL-2. 17
Background: This landmark study is one of few carried
out in melanoma that speciﬁcally examined the role
of systemic interleukin-2 in patients with stage IV
melanoma.
Methods: In this study, 363 patients were randomized
to receive dacarbazine 250mg/m2 and cisplatin 30 mg/m2
on days 1−3 combined with interferon-alfa-2b 10MU/m2
subcutaneously on days 1 through 5 without (arm A)
or with (arm B) a high-dose intravenous decrescendo
regimen of IL-2 on days 5 through 10 (18MU/m2/6 hours,
18MU/m2/12 hours, 18MU/m2/24 hours, and 4.5MU/m2
for 3×24 hours). Treatment was given every 28 days to a
maximum of 4 cycles or until disease progression.
Results: This study recruited 363 patients with ad-
vanced metastatic disease. The median survival was
9months in both arms,with a 2-year OS rate of 12.9% and
17.6% in arms A and B, respectively (HR=0.90, 95%CI
0.72–1.11; P = 0.32). In addition, there was no statistically
signiﬁcant difference regarding PFS (median, 3.0 versus
3.9 months) and response rate (22.8% versus 20.8%).
Conclusion: Despite its activity in melanoma as a single
agent or in combination with interferon-alfa-2b, the cho-
sen schedule of IL-2 added to the chemoimmunotherapy
combination had no clinically relevant efﬁcacy.
2.3.3. Translational research project linked to EORTC trial
18951
Background: As elevated count of blood neutrophils and
monocytes had been shown to independently predict
short survival in patients with stage IV melanoma
undergoing interleukin-2-based immunotherapy, neu-
trophil and leukocyte counts were analyzed together
with other known prognostic factors like serum lactate
dehydrogenase, performance status, metastatic site,
and sex in the EORTC 18951 study population. Two
multivariate prognostic factor analyses were performed
in the model: one with leukocyte counts and one with
neutrophil counts.
Results: Counts of baseline blood neutrophil and
leukocyte were available from 316 and 350 patients,
respectively. A high neutrophil count (>7.5×109/L) was
an independent prognostic factor for short OS (HR=1.5,
95%CI 1.1−2.1; P = 0.02), and a high leukocyte count
(>10×109/L) was an independent prognostic factor of both
short OS (HR=1.7, 95%CI 1.3−2.4; P = 0.0005) and short PFS
(HR=1.5, 95%CI 1.1−2.1; P = 0.008). 18
Conclusion: This retrospective prognostic study has
conﬁrmed that a high pretreatment count of neutrophils
in blood is indeed an independent prognostic factor for
short OS in stage IV melanoma patients undergoing
interleukin-2-based immunotherapy. Moreover, a high
count of leukocytes was found to be an independent
prognostic factor for short OS and PFS.
2.3.4. EORTC 16032-18031 − Immunization with the
recombinant MAGE-3 protein combined with adjuvant AS02B
or AS15 in patients with unresectable and progressive
metastatic cutaneous melanoma. 19
Background: Earlier studies showed that active immuniza-
tion against the tumor-speciﬁc MAGE-A3 antigen was
followed by a few but deﬁnite clinical responses. In a bid
to increase this anti-tumor activity, this randomized
Phase II trial in stage IV melanoma was performed to
evaluate immunization with the recombinant MAGE-A3
protein combined with two different immunostimu-
lants.
Methods: Patients with MAGE-A3-positive in-transit or
unresectable stage III or stage IV M1a melanoma were
randomly assigned to receive as ﬁrst-line treatment
the recombinant MAGE-A3 protein combined either
with AS02B or with AS15 immunostimulant. Clinical
endpoints were toxicity and rates of objective clinical
responses (OR), PFS and OS.
Results: Thirty-six patients were accrued to both arms.
Both treatments were equally well tolerated. In the AS15
arm, four OR were observed (three CR and one PR) and
only one PR in the AS02B arm. The PFS at six months was
25% versus 14% and the median OS 33.0 months versus
19.9 months with a median follow-up of 48 months.
Antibodies against MAGE-A3 were found in all patients,
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with a three-fold higher titer in the AS15 arm. The anti-
MAGE-A3 cellular response was also more pronounced in
the AS15 arm.
Conclusions: This very important study with a very
large translational research component demonstrated
that clinical activity appeared to be higher in the
MAGE-A3+AS15 arm, together with a more robust cellular
and humoral immune response and without relevant
toxicity. Therefore the AS15 immunostimulant has been
selected for combination with the recombinant MAGE-A3
protein in phase III trials.
2.4. Chemotherapy
2.4.1. EORTC trial 18032 − Extended schedule, escalated dose
temozolomide versus dacarbazine in stage IV metastatic
melanoma: a randomized phase III study of the EORTC
Melanoma Group 20
Background: With the imminent development of new
small molecule targeted therapies, it was important
to deﬁne the standard chemotherapy regimen against
which new agents should be compared or with which
they should be combined.
Purpose: EORTC trial 18032, the largest trial in
stage IV melanoma to have been carried out at the
time, compared the efﬁcacy of an extended schedule,
escalated-dose of temozolomide, that delivered a higher
dose of temozolomide than previous regimens, versus
standard-dose dacarbazine in stage IV melanoma.
Patients and Methods: A total of 859 patients were ran-
domized to receive oral temozolomide at 150mg/m2/day
for 7 consecutive days every 2 weeks or dacarbazine, ad-
ministered as an intravenous infusion at 1000mg/m2/day
on day 1 every 3 weeks. The primary endpoint was OS
using an intent-to-treat principle.
Results: There was no difference in OS or PFS. The
median OS was 9.1 months in the temozolomide arm
and 9.4 months in the dacarbazine arm with a HR
of 1.00 (95%CI 0.86–1.17; P = 0.99). Median PFS was
2.3 months in the temozolomide arm and 2.2 months
in the dacarbazine arm, with a HR of 0.92 (95%CI
0.80–1.06; P = 0.27). The most common non-hematologic
treatment-emergent adverse events reported in both
treatment arms were nausea, fatigue, and vomiting and
constipation.
Conclusion: Extended schedule escalated-dose temo-
zolomide (7 days on, 7 days off) is feasible and has an
acceptable safety proﬁle but does not improve OS and PFS
in metastatic melanoma when compared to standard-
dose dacarbazine.
2.5. Rare tumor initiative
Ocular melanoma is a rare disease, and the EORTC
network is ideally placed to address the therapeutic
challenges in this area. Initially through collaboration
with the EORTC Ophthalmic Oncology Task Force and
more recently by incorporating an Ocular Melanoma
subcommittee in its structure, the EORTC MG is
working on trials in this difﬁcult area. EORTC trial
18021 of intrahepatic versus intravenous fotemustine has
recruited more than any other randomized trial in this
area and will report its ﬁndings shortly. This resulted
in the creation of a speciﬁc network of more than 30
institutions in 10 European countries which was able to
conduct high-quality trials in this rare disease. A study
exploring the combination of bleomycin, vincristine,
lomustine, and dacarbazine (BOLD) in combination with
recombinant interferon alpha-2b for metastatic uveal
melanoma was conducted. 21 EORTC trial 18021 of
intrahepatic versus intravenous fotemustine for stage IV
metastatic ocular melanoma has recruited more than
any other randomized trials in this area and will report
its ﬁndings shortly.
2.6. Translational research
The EORTC MG has a long and distinguished track
record of translation research both within its trials and
within the network’s multi-disciplinary expertise. Good
prognostic markers have been identiﬁed for cutaneous
melanoma, yet little is known about their biological
signiﬁcance. Therefore, understanding the correlations
between the prognostic factors and the biology of the
disease is a major objective of melanoma translational
research. 22
In 2004, the EORTC MG conducted the ﬁrst genomics
study on a large cohort of primary melanomas using
more than 105 validated frozen primary tumor samples.
The correlation of gene-expression proﬁles with clinical
outcome led to a signature based on 60 genes
discriminating between primary melanomas associated
with good and poor prognosis. Key pathways associated
with melanoma progression have been identiﬁed. 23
The EORTC MG has played an important role in
systematically evaluating prognostic and predicative
markers including serum markers, immunological mark-
ers and RT-PCR for circulating tumor cells. In the
process it has developed quality assurance programs for
immunological assays and molecular biological assays
such as RT-PCR, S100B as a soluble marker of melanoma,
TNFalpha and Melphalan combination in isolated limb
perfusions, 24 as well as in patients’ sera in EORTC trial
18952. 25,26 The ﬁndings highlighted the origin, half-life,
and the value of serial S100B blood measurements in the
follow-up and management of the disease.
The group has shown the importance of neutrophil
count in predicting outcome in advanced melanoma 18
and evaluated RT-PCR-detected circulating tumor cells. 27
Importantly the group has examined the utility of
autoantibodies in predicting response to interferon and
demonstrated the absence of predictive value. 27,28
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The pathology committee has played an important
role in setting standards for central pathology review
and quality assurance for the EORTC MG trials and has
published a number of important papers on criteria and
guidelines in the ﬁeld of dysplastic naevi, melanoma
in childhood and melanoma staging systems. 29−31 The
diagnosis of melanoma in childhood is marred with
pitfalls and the diagnosis is often incorrect. In a
review/reassessment of >100 cases by the EORTC MG
pathologist-panel it was concluded that in almost half
the cases the diagnosis melanoma was incorrect. 32 At
present, the EORTC MG is a full partner in the EU
telematics project that aims to improve exchange of
diagnostic images through a European network.
Another focus of studies performed by the pathol-
ogy committee has been the expression of various
classes of antigen in primary, regionally metastatic
and distant metastatic melanoma. The EORTC MG
carried out the most extensive inventory study on
the use of monoclonal antibodies in the early 1990’s
and documented changes of expression under cytokine
treatments. 33,34 The differential expression of antigens
in relation to the progression of the disease was shown
to have important implications for both diagnosis as
well as immunotherapeutic treatment strategies. 35 In
yet another study on the EORTC MG primary melanoma
material it was demonstrated that high tPA expression
in primary melanoma of the limb correlates with good
prognosis. 36 The pathology group led the research into
identifying pathological markers in sentinel lymph node
biopsies (section 2.1).
2.7. Collaboration with other groups
The EORTC MG has a productive cooperation with
European Society for Pigment Cell Research (ESPCR)
with the aim of increasing the collaboration between
basic and clinical research in melanoma. On the clinical
side, cooperative studies were launched with the WHO
Melanoma Program, the Scandinavian Melanoma Group
and the North American Perfusion Group.
3. Future strategy
The EORTC MG is committed to further execute and
expand a comprehensive melanoma program through
the fully integrated and collaborative approach by its
member scientists and clinicians. Molecular therapeutics
and immunotherapy will be an important focus for
the next decade as is the ever challenging task of
identifying a systemic adjuvant therapy regimen for
high-risk melanoma that is effective enough to be
accepted as standard of care and a stepping stone for
further developments.
Recent developments in immune and targeted therapy
have opened new therapeutic perspectives for metastatic
melanoma patients. Both modalities act via distinct
mechanisms; targeting MAPK pathway induces rapid
responses at high rate, however, drug resistance develops
in the vast majority of patients. On the other hand,
response rates to immunotherapy are rather low, but
remarkably, responding patients in general have long-
lasting clinical beneﬁt. We now face the challenge to
exploit these novel approaches selectively and effectively
in order to achieve long-term tumor control.
In the ﬁeld of genetic and epidemiology studies,
the time for a molecular genetic and epidemiological
program has arrived and innovative studies will be
launched in that ﬁeld. The membership of the group will
grow further and incorporate especially scientists from
ﬁelds of research such as genetics and genomics. The
EORTC MG is thus headed for even more exciting times
in its existence.
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